Searchable abstracts of presentations at key conferences in endocrinology

ea0056p1139 | Thyroid cancer | ECE2018

Tyrosine kinase inhibitor (TKI) treatment outcome of stage IV-C thyroid differentiated cancer (analyzed by lesion evaluation)

Iwasaki Hiroyuki , Yamazaki Haruhiko , Suganuma Nobuyasu , Sugawara Yuko , Gotoh Naoki , Hatori Shinsuke , Nakayama Hirotaka , Masudo Katsuhiko

Introduction: The standard treatment for differentiated thyroid carcinoma (DTC) with distant metastasis comprises complete total thyroidectomy and lymph node dissection, followed by radioactive iodine (RAI) ablation for metastatic lesions. However, between 2014 and 2015, sorafenib and lenvatinib have been approved for treatment of RAI-refractory advanced thyroid cancer in Japan. We retrospectively analyzed how the treatment results have changed after the approval of tyrosine k...

ea0056p1140 | Thyroid cancer | ECE2018

Expression of VEGFR2 and clinical response of anaplastic thyroid cancer to lenvatinib

Yamazaki Haruhiko , Iwasaki Hiroyuki , Suganuma Nobuyasu , Yokose Tomoyuki , Hayashi Hiroyuki , Osanai Sachie , Masudo Katsuhiko , Nakayama Hirotaka , Kohagura Kaori , Rino Yasushi , Masuda Munetaka

Introduction: Angiogenesis is known to play an important role in the development, growth, and metastasis of carcinomas. The vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) are major molecules involved in angiogenesis. The VEGF family includes seven members, respectively named VEGF-A (often simply denoted as VEGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and placental growth factor. The VEGFR is a tyrosine kinase receptor with one to three types and is activ...